Use of dynamic contrast-enhanced MRI to measure subtle blood–brain barrier abnormalities
✍ Scribed by Paul A. Armitage; Andrew J. Farrall; Trevor K. Carpenter; Fergus N. Doubal; Joanna M. Wardlaw
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 650 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0730-725X
No coin nor oath required. For personal study only.
✦ Synopsis
There is growing interest in investigating the role of subtle changes in blood–brain barrier (BBB) function in common neurological disorders and the possible use of imaging techniques to assess these abnormalities. Some studies have used dynamic contrast-enhanced MR imaging (DCE-MRI) and these have demonstrated much smaller signal changes than obtained from more traditional applications of the technique, such as in intracranial tumors and multiple sclerosis. In this work, preliminary results are presented from a DCE-MRI study of patients with mild stroke classified according to the extent of visible underlying white matter abnormalities. These data are used to estimate typical signal enhancement profiles in different tissue types and by degrees of white matter abnormality. The effect of scanner noise, drift and different intrinsic tissue properties on signal enhancement data is also investigated and the likely implications for interpreting the enhancement profiles are discussed. No significant differences in average signal enhancement or contrast agent concentration were observed between patients with different degrees of white matter abnormality, although there was a trend towards greater signal enhancement with more abnormal white matter. Furthermore, the results suggest that many of the factors considered introduce uncertainty of a similar magnitude to expected effect sizes, making it unclear whether differences in signal enhancement are truly reflective of an underlying BBB abnormality or due to an unrelated effect. As the ultimate aim is to achieve a reliable quantification of BBB function in subtle disorders, this study highlights the factors which may influence signal enhancement and suggests that further work is required to address the challenging problems of quantifying contrast agent concentration in healthy and diseased living human tissue and of establishing a suitable model to enable quantification of relevant physiological parameters. Meanwhile, it is essential that future studies use an appropriate control group to minimize these influences.
📜 SIMILAR VOLUMES
## Abstract Breakdown of the blood‐brain barrier (BBB), occurring in many neurological diseases, has been difficult to measure noninvasively in humans. Dynamic contrast‐enhanced magnetic resonance imaging measures BBB permeability. However, important technical challenges remain and normative data f
## Abstract ## Purpose: To design a more accurate and reproducible technique for the measurement of blood–brain barrier (BBB) permeability in gadolinium‐enhancing multiple sclerosis (MS) lesions. ## Materials and Methods: Four MS patients were scanned using a new dynamic contrast‐enhanced (DCE)‐
## Abstract Breakdown of the blood‐retinal barrier (BRB), frequently an early clinical sign in retinopathy, can be accurately determined using contrast‐enhanced MRI. However, increased vitreous fluidity with age and disease may affect the accuracy of the MRI method. We compared the permeability sur
## Abstract Dextran‐magnetite particles (DMP) were studied for their use as a MR contrast agent to visualize lesions with a blood‐brain barrier (bbb) disruption. A freezing injury to the rat cerebral cortex was used as a model of bbb disruption. The biodistribution of iv‐injected DMP was studied us